Drug induced and toxic liver injury
Authors:
Ondřej Fabián 1,2; Eva Sticová 1,3,4
Authors‘ workplace:
Pracoviště klinické a transplantační patologie, Institut klinické a experimentální medicíny, Vídeňská 9, 140 21, Praha 4
1; Ústav patologie a molekulární medicíny 3. LF UK a FTN, Vídeňská 800, 140 59, Praha 4
2; Ústav patologie, Fakultní nemocnice Královské Vinohrady, Šrobárova 1150/50, 100 34, Praha 10
3; Cellular Pathology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK
4
Published in:
Čes.-slov. Patol., 62, 2026, No. 3, p. 178-192
Category:
Reviews Article
Overview
Drug-Induced Liver Injury (DILI) is a common yet diagnostically challenging cause of liver damage. It can be triggered by a wide range of medications, herbal remedies, dietary supplements, recreational drugs, industrial chemicals, and natural toxins, and its clinical and morphological presentation is highly variable. This review summarizes the principal pathogenetic mechanisms of liver injury and discusses the histopathological diagnosis of DILI. Although histopathology rarely allows definitive identification of the causative agent, it helps define the pattern of injury, assess its severity, and support clinical suspicion. The article provides an overview of the major morphological patterns of injury, including hepatocellular necrosis, acute and chronic hepatitis, cholestasis, steatosis and steatohepatitis, vascular lesions, granulomas, hypersensitivity-type injury, and tumor-like lesions. The most important hepatotoxic agents encountered in routine liver biopsy practice are also reviewed.
Keywords:
histopathology – drug-induced liver injury – DILI – hepatotoxicity – liver biopsy
Sources
1. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the spanish registry over a 10-year period. Gastroenterology 2005; 129(2): 512-521.
2. Bjornsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in sweden. Scand J Gastroenterol 2005; 40(9): 1095-1101.
3. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the united states. Gastroenterology 2008; 135(6): 1924-1934, 1934 e1921-1924.
4. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32(1 Suppl): 77-88.
5. Devarbhavi H, Karanth D, Prasanna KS, Adarsh CK, Patil M. Drug-induced liver injury with hypersensitivity features has a better outcome: A single-center experience of 39 children and adolescents. Hepatology 2011; 54(4): 1344-1350.
6. Grieco A, Vecchio FM, Greco AV, Gasbarrini G. Cholestatic hepatitis due to ticlopidine: Clinical and histological recovery after drug withdrawal. Case report and review of the literature. Eur J Gastroenterol Hepatol 1998; 10(8): 713-715.
7. Hoofnagle JH, Bjornsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med 2019; 381(3): 264-273.
8. Neuberger J. Halothane hepatitis. Eur J Gastroenterol Hepatol 1998; 10(8): 631-633.
9. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--i. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol 1993; 46(11): 1323-1330.
10. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11(2): 272-276. 11. Lindgren A, Aldenborg F, Norkrans G, Olaison L, Olsson R. Paracetamol-induced cholestatic and granulomatous liver injuries. J Intern Med 1997; 241(5): 435-439.
12. Portmann B, Talbot IC, Day DW, et al. Histopathological changes in the liver following a paracetamol overdose: Correlation with clinical and biochemical parameters. J Pathol 1975; 117(3): 169-181.
13. Perino LE, Warren GH, Levine JS. Cocaine - -induced hepatotoxicity in humans. Gastroenterology 1987; 93(1): 176-180.
14. De La Monte SM, Arcidi JM, Moore GW, Hutchins GM. Midzonal necrosis as a pattern of hepatocellular injury after shock. Gastroenterology 1984; 86(4): 627-631.
15. Wepler W, Opitz K. Histologic changes in the liver biopsy in amanita phalloides intoxication. Hum Pathol 1972; 3(2): 249-254.
16. Mitchell I, Wendon J, Fitt S, Williams R. Anti-tuberculous therapy and acute liver failure. Lancet 1995; 345(8949): 555-556.
17. Fogden E, Neuberger J. Alternative medicines and the liver. Liver Int 2003; 23(4): 213 - 220.
18. Paterson D, Kerlin P, Walker N, Lynch S, Strong R. Piroxicam induced submassive necrosis of the liver. Gut 1992; 33(10): 1436 - 1438. 19. Ouellette GS, Slitzky BE, Gates JA, Lagarde S, West AB. Reversible hepatitis associated with diclofenac. J Clin Gastroenterol 1991; 13(2): 205-210.
20. Watanabe A, Nishida T, Osugi N, et al. 5-aminosalicylic acid-induced liver injury in a patient with ulcerative colitis: A case report. Case Rep Gastroenterol 2024; 18(1): 39-48.
21. Gloria L, Serejo F, Cruz E, et al. Diphenylhydantoin-induced hepatitis: A case report. Hepatogastroenterology 1998; 45(20): 411-414.
22. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44(5): 731-735.
23. Kleiner DE. Histopathological challenges in suspected drug-induced liver injury. Liver Int 2018; 38(2): 198-209.
24. Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. Hepatology 2014; 59(2): 661-670.
25. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis. Hepatology 2010; 51(6): 2040-2048.
26. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011; 56(4): 958-976.
27. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011; 54(3): 931-939.
28. Jorens PG, Michielsen PP, Pelckmans PA, et al. Vitamin a abuse: Development of cirrhosis despite cessation of vitamin a. A six-year clinical and histopathologic follow-up. Liver 1992; 12(6): 381-386.
29. Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006; 44(4): 778-787.
30. Sanchez-Osorio M, Duarte-Rojo A, Martinez-Benitez B, Torre A, Uribe M. Anabolic - -androgenic steroids and liver injury. Liver Int 2008; 28(2): 278-282.
31. Ishak KG. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1981; 1(2): 116-128.
32. Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology 1999; 29(5): 1347-1351.
33. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ats statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174(8): 935-952.
34. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions. Hepatology 1995; 22(3): 820-827.
35. Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997; 26 Suppl 1(31-35.
36. Ryley NG, Fleming KA, Chapman RW. Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (augmentin). J Hepatol 1995; 23(3): 278-282.
37. Castiella A, Lopez-Dominguez L, Sanchez-Iturri MJ, et al. Liver steatosis in patients with rheumatoid arthritis treated with methotrexate is associated with body mass index. World J Hepatol 2023; 15(5): 699-706.
38. Rahimi L, Rajpal A, Ismail-Beigi F. Glucocorticoid-induced fatty liver disease. Diabetes Metab Syndr Obes 2020; 13(1133-1145.
39. Landas SK, Mitros FA, Furst DE, Labrecque DR. Lipogranulomas and gold in the liver in rheumatoid arthritis. Am J Surg Pathol 1992; 16(2): 171-174.
40. Kleiner DE, Gaffey MJ, Sallie R, et al. Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 1997; 10(3): 192-199.
41. Chariot P, Drogou I, De Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30(1): 156 - 160.
42. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: Mechanisms and test systems. Hepatology 2001; 33(4): 1009-1013.
43. Tennant BC, Baldwin BH, Graham LA, et al. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis b virus infection. Hepatology 1998; 28(1): 179-191.
44. Seki K, Minami Y, Nishikawa M, et al. “Nonalcoholic steatohepatitis” induced by massive doses of synthetic estrogen. Gastroenterol Jpn 1983; 18(3): 197-203.
45. Harrison RF, Elias E. Amiodarone-associated cirrhosis with hepatic and lymph node granulomas. Histopathology 1993; 22(1): 80-82. 46. Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis. Ann Intern Med 1996; 124(9): 855-856.
47. Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94(3): 274-286.
48. Lewis JH, Mullick F, Ishak KG, et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990; 21(1): 59-67.
49. Munoz SJ, Martinez-Hernandez A, Maddrey WC. Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim-sulfamethoxazole. Hepatology 1990; 12(2): 342-347.
50. Zafrani ES, Von Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med 1983; 143(3): 495-502.
51. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009; 62(6): 481-492.
52. Vanderstigel M, Zafrani ES, Lejonc JL, Schaeffer A, Portos JL. Allopurinol hypersensitivity syndrome as a cause of hepatic fibrin-ring granulomas. Gastroenterology 1986; 90(1): 188-190.
53. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J (Clin Res Ed) 1986; 292(6532): 1355-1357.
54. Winberg CD, Ranchod M. Thorotrast induced hepatic cholangiocarcinoma and angiosarcoma. Hum Pathol 1979; 10(1): 108-112.
55. Kozielewicz DM, Stalke P, Skrzypek J. Drug - -induced liver injury. Part i: Classification, diagnosis and treatment. Clin Exp Hepatol 2025; 11(1): 25-33.
56. Lefkowitch JH, Lobritto SJ, Brown RS, Jr., et al. Ground-glass, polyglucosan-like hepatocellular inclusions: A “new” diagnostic entity. Gastroenterology 2006; 131(3): 713-718.
57. Maronpot RR, Yoshizawa K, Nyska A, et al. Hepatic enzyme induction: Histopathology. Toxicol Pathol 2010; 38(5): 776-795.
58. Lopez-Rocha E, Blancas L, Rodriguez-Mireles K, et al. Prevalence of dress syndrome. Rev Alerg Mex 2014; 61(1): 14-23.
59. Cacoub P, Musette P, Descamps V, et al. The dress syndrome: A literature review. Am J Med 2011; 124(7): 588-597.
60. Ichai P, Laurent-Bellue A, Saliba F, et al. Acute liver failure/injury related to drug reaction with eosinophilia and systemic symptoms: Outcomes and prognostic factors. Transplantation 2017; 101(8): 1830-1837.
61. Roenigk HH, Jr., Auerbach R, Maibach HI, Weinstein GD. Methotrexate guidelines- - revised. J Am Acad Dermatol 1982; 6(2): 145 - 155.
62. James O, Lesna M, Roberts SH, et al. Liver damage after paracetamol overdose. Comparison of liver-function tests, fasting serum bile acids, and liver histology. Lancet 1975; 2(7935): 579-581.
63. Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11(3): 563-575, vi-vii.
64. Boelsterli UA. Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003; 192(3): 307-322.
65. Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol 1996; 91(8): 1626-1630.
66. Kimura S, Kobayashi T, Tanaka Y, Sasaki Y. Liver histopathology in clinical reye syndrome. Brain Dev 1991; 13(2): 95-100.
67. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9(5): 679-685.
68. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009; 29(4): 412-422.
69. Goodrum JF, Fowler KA, Hostettler JD, Toews AD. Peripheral nerve regeneration and cholesterol reutilization are normal in the low-density lipoprotein receptor knockout mouse. J Neurosci Res 2000; 59(4): 581-586.
70. Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol 2008; 23(2): 192-202.
71. Altman C, Biour M, Grange JD. [hepatic toxicity of antitubercular agents. Role of different drugs. 199 cases]. Presse Med 1993; 22(26): 1212-1216.
72. Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from spain. Hepatology 2006; 44(4): 850-856.
73. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 1992; 33(3): 368-371.
74. Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 2005; 50(10): 1785-1790.
75. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects - - review of the literature. Eur J Med Res 2001; 6(4): 139-149.
76. Quintin E, Scoazec JY, Marotte H, Miossec P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther 2010; 12(4): R143.
77. Whiting-O’keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: A meta-analysis. Am J Med 1991; 90(6): 711-716.
78. Romagnuolo J, Sadowski DC, Lalor E, Jewell L, Thomson AB. Cholestatic hepatocellular injury with azathioprine: A case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998; 12(7): 479-483.
79. Jacobi AM, Feist E, Rudolph B, Burmester GR. Sinusoidal dilatation: A rare side effect of azathioprine. Ann Rheum Dis 2004; 63(12): 1702-1703.
80. Mion F, Napoleon B, Berger F, et al. Azathioprine induced liver disease: Nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 1991; 32(6): 715-717.
81. Adler M, Delhaye M, Deprez C, et al. Hepatic vascular disease after kidney transplantation: Report of two cases and review of the literature. Nephrol Dial Transplant 1987; 2(3): 183-188.
82. Worland T, Chin KL, Van Langenberg D, Garg M, Nicoll A. Retrospective study of idiosyncratic drug-induced liver injury from infliximab in an inflammatory bowel disease cohort: The idle study. Ann Gastroenterol 2020; 33(2): 162-169.
83. Ricciuto A, Kamath BM, Walters TD, et al. New onset autoimmune hepatitis during anti-tumor necrosis factor-alpha treatment in children. J Pediatr 2018; 194(128-135 e121.
84. Kallinowski B, Theilmann L, Zimmermann R, et al. Effective treatment of cyclosporine - -induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid. Transplantation 1991; 51(5): 1128-1129.
85. Loertscher R, Wenk M, Harder F, et al. Hyperbilirubinaemia and cyclosporin a levels in renal transplant patients. Lancet 1981; 2(8247): 635-636.
86. Riveiro-Barciela M, Barreira-Diaz A, Vidal - -Gonzalez J, et al. Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. Liver Int 2020; 40(8): 1906 - 1916.
87. De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018; 68(6): 1181 - 1190.
88. Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: Pathologists’ perspective. J Clin Pathol 2018; 71(8): 665-671.
89. Zhang D, Hart J, Ding X, et al. Histologic patterns of liver injury induced by anti-pd-1 therapy. Gastroenterol Rep (Oxf) 2020; 8(1): 50-55.
90. Zen Y, Chen YY, Jeng YM, Tsai HW, Yeh mm. Immune-related adverse reactions in the hepatobiliary system: Second-generation check - -point inhibitors highlight diverse histological changes. Histopathology 2020; 76(3): 470-480.
91. Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26(3): 353-365.
92. Leal S, Rocha L, Silva A, et al. Evaluation of progressive hepatic histopathology in long-term tamoxifen therapy. Pathol Res Pract 2018; 214(12): 2115-2120.
93. Lewis JH, Tice HL, Zimmerman HJ. Budd - -chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases. Dig Dis Sci 1983; 28(8): 673-683.
94. Steinbrecher UP, Lisbona R, Huang SN, Mishkin S. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci 1981; 26(11): 1045 - 1050.
95. European Association for the Study of The L. Easl clinical practice guidelines: Drug-induced liver injury. J Hepatol 2019; 70(6): 1222 - 1261.
96. Byeon JH, Kil JH, Ahn YC, Son CG. Systematic review of published data on herb induced liver injury. J Ethnopharmacol 2019; 233(190 - 196.
97. Zhu J, Seo JE, Wang S, et al. The development of a database for herbal and dietary supplement induced liver toxicity. Int J Mol Sci 2018; 19(10):
98. Lin NH, Yang HW, Su YJ, Chang CW. Herb induced liver injury after using herbal medicine: A systemic review and case-control study. Medicine (Baltimore) 2019; 98(13): e14992.
99. Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin a. Am J Clin Nutr 2006; 83(2): 191-201.
100. Chiu YK, Lai MS, Ho JC, Chen JB. Acute fish liver intoxication: Report of three cases. Changgeng Yi Xue Za Zhi 1999; 22(3): 468-473. 101. Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin a administration: Estimate of dose - -related toxicity in 41 cases. Gastroenterology 1991; 100(6): 1701-1709.
Labels
Anatomical pathology Forensic medical examiner ToxicologyArticle was published in
Czecho-Slovak Pathology
2026 Issue 3
-
All articles in this issue
- Léky indukované změny v histopatologii
- Setkání s každým člověkem je obohacující…
- MONITOR aneb nemělo by vám uniknout, že...
- Iatrogenic injury of the gastrointestinal tract
- Morphological aspects of drug-induced cutaneous reactions
- Drug induced and toxic liver injury
- Drug-Induced Nephropathies from the Pathologist‘s Perspective
- Immunotherapy Adverse Events in the Treatment of Solid Tumors
- Mature B-cell Non-Hodgkin Lymphomas in Children and Young Adults: The Same Diseases as in Adults or Distinct Entities?
- Pseudomyogenic hemangioendothelioma
- Czecho-Slovak Pathology
- Journal archive
- Current issue
- Online only
- About the journal
Most read in this issue
- Drug induced and toxic liver injury
- Léky indukované změny v histopatologii
- Morphological aspects of drug-induced cutaneous reactions
- Setkání s každým člověkem je obohacující…